drugset / Trial / NCT02194998

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998

Non-randomizedParallel-groupOpen-labelTreatment

Summary

HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV. Interferon (IFN) is a drug used to treat HCV; however, in people coinfected with HIV and HCV, IFN treatment often does not work well and can cause unwanted side effects. The purpose of this study was to evaluate the safety, tolerability, and effectiveness of IFN-free HCV treatment in HIV/HCV coinfected adults who were taking antiretroviral (ARV) therapy.

Timeline

Start
2015-09-16
Primary completion
2018-05-17
Completion
2018-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg Oral
Subject Ribavirin Small molecule 1200 mg Oral
Subject Ritonavir Other / unclassified 100 mg Oral
Subject dasabuvir Small molecule 250 mg Oral
Subject ombitasvir Small molecule 25 mg Oral
Subject paritaprevir Small molecule 150 mg Oral